Evidence map›Paper›PMID 35362891›Full record

ArticleAnnals of nuclear medicine2022

Time point-independent tumor positivity of

Sijuan Zou, Shuang Song, Jianyuan Zhou, Bo Yu, Dong Kuang, Zhihua Wang, Xiaohua Zhu

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of nuclear medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sijuan ZouDepartment of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan, 430030, Hubei, China.
Shuang SongDepartment of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan, 430030, Hubei, China.
Jianyuan ZhouDepartment of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan, 430030, Hubei, China.
Bo YuDepartment of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan, 430030, Hubei, China.
Dong KuangDepartment of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhihua WangDepartment of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xiaohua ZhuDepartment of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan, 430030, Hubei, China. evazhu@vip.sina.com.ORCID http://orcid.org/0000-0003-0495-9510
Tongji Hospital · CN

Funding

National Natural Science Foundation of China 81873903National Natural Science Foundation of China 91959119Natural Science Foundation of Hubei Province 2020CFB586
6 · The paper itself

Abstract

objectiveProstate-specific membrane antigen (PSMA)-PET/CT imaging has gained increasing clinical importance for the detection and staging of high-risk primary prostate cancer (PCa). However, it is unclear whether the routine practice of prostate biopsy obscures the image finding of PSMA-PET/CT. This study aimed to compare the tumor positivity rate of PSMA-PET/CT performed pre- (PSMA-PET/CT PATIENTS AND

methodsWe matched 58 PSMA-PET/CT

resultsAll the primary tumors were positive on PSMA-PET/CT

conclusionsThe tumor positivity rate was consistently high for PSMA-PET/CT pre- and post-biopsy. A prior biopsy does not seem to affect the tumor positivity rate of PSMA-PET/CT in high-risk PCa.

Indexed as

Positron Emission Tomography Computed TomographyProstatic NeoplasmsBiopsyGallium IsotopesGallium RadioisotopesHumansMalegallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesHigh riskPositron emission tomography (PET)/computed tomography (CT)Prostate biopsyProstate cancerProstate-specific membrane antigen (PSMA)

Identifiers

PMID35362891
PMCPMC9132805
OpenAlexW4221104258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.